Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer

[1]  C. Rödel,et al.  Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer , 2013, Radiation Oncology.

[2]  J. Hecht,et al.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. , 2012, The Lancet. Oncology.

[3]  Torsten Hothorn,et al.  Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. , 2012, The Lancet. Oncology.

[4]  P. Kienle,et al.  Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. , 2012, The Lancet. Oncology.

[5]  D. Tait,et al.  Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  F. Zimmermann,et al.  Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer , 2012, Strahlentherapie und Onkologie.

[7]  Tanja Fehm,et al.  Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. , 2012, The New England journal of medicine.

[8]  H. Kennecke,et al.  Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. , 2012, European journal of cancer.

[9]  J. Shipley,et al.  Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. , 2012, International journal of radiation oncology, biology, physics.

[10]  W. Hohenberger,et al.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Bracko,et al.  Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study , 2011, Radiation oncology.

[12]  Vincenzo Valentini,et al.  Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Boni,et al.  Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Tang,et al.  The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N. Petrelli,et al.  The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Van Cutsem,et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Shenhong Wu,et al.  Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. , 2011, JAMA.

[18]  N. Petrelli,et al.  Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Greil,et al.  Preoperative Oxaliplatin, Capecitabine, and External Beam Radiotherapy in Patients with Newly Diagnosed, Primary Operable, cT3NxM0, Low Rectal Cancer , 2011, Strahlentherapie und Onkologie.

[20]  Karin Haustermans,et al.  Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. , 2010, The Lancet. Oncology.

[21]  Jeffrey W. Clark,et al.  A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. , 2010, The oncologist.

[22]  S. Curley,et al.  Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases , 2010, Annals of Surgical Oncology.

[23]  Christophe Hennequin,et al.  Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Ellis,et al.  Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. , 2010, International journal of radiation oncology, biology, physics.

[25]  Markus Klinger,et al.  Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX , 2010, Annals of Surgical Oncology.

[26]  N. Ferris,et al.  Preoperative staging of rectal cancer. , 2009, Future oncology.

[27]  Jeffrey W. Clark,et al.  Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L. Ellis,et al.  Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  F. Lordick,et al.  Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. , 2008, International journal of radiation oncology, biology, physics.

[30]  L. Ellis,et al.  Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases , 2007, Cancer.

[31]  John Thomas,et al.  Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. , 2007, International journal of radiation oncology, biology, physics.

[32]  F. Lordick,et al.  Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Bernard Leduc,et al.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Laurence Collette,et al.  Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.

[35]  Rainer Fietkau,et al.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  E. Venkatraman,et al.  The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. , 2005, International journal of radiation oncology, biology, physics.

[37]  M. Mazumdar,et al.  Long-term Oncologic Outcome Following Preoperative Combined Modality Therapy and Total Mesorectal Excision of Locally Advanced Rectal Cancer , 2005, Annals of surgery.

[38]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[39]  N. Ferrara.  Vascular endothelial growth factor as a target for anticancer therapy. , 2004, The oncologist.

[40]  Daniel J Sargent,et al.  Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[42]  W. Hohenberger,et al.  Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  D. Rothenberger,et al.  A Pathologic Complete Response to Preoperative Chemoradiation Is Associated With Lower Local Recurrence and Improved Survival in Rectal Cancer Patients Treated by Mesorectal Excision , 2003, Diseases of the colon and rectum.

[44]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  L. Ellis,et al.  Improved Overall Survival Among Responders to Preoperative Chemoradiation for Locally Advanced Rectal Cancer , 2001, American journal of clinical oncology.

[46]  G. Hill,et al.  Preoperative staging of rectal cancer , 2000, International Journal of Colorectal Disease.

[47]  S. Andreola,et al.  Pathological features of rectal cancer after preoperative radiochemotherapy , 1998, International Journal of Colorectal Disease.